Lecture Series *CCC-N Cancer Club*

Prof. Dr. med. Günter Schneider (UMG), PD Dr. Matthias Wirth (UMG),
and PD Dr. Anna Saborowski (MHH)

(previous co-organizers: Gudrun Göhring (MHH), Anke Bergmann (MHH))

List of previous talks in the series:

1. 07.02.2022
   Dr. med. Raphael Koch, Department of Hematology and Medical Oncology (UMG)
   Exploring functional vulnerabilities in T-cell lymphoma and beyond
2. 07.03.2022
   Prof. Dr. med. Klaus Pantel, Institute of Tumor Biology (UKE Hamburg)
   Liquid Biopsy: From Discovery to Clinical Implementation
3. 25.04.2022
   PD Dr. med. Thomas Wirth, Department of Gastroenterology, Hepatology and Endocrinology (MHH)
   Immunotherapy of GI Cancers. From Checkpoint Inhibition to Personalized Vaccines
4. 16.05.2022
   PD Dr. Dr. Lena Conradi, Department of General, Visceral and Pediatric Surgery (UMG)
   Vessel Co-option versus Angiogenesis in Colorectal Cancer Liver Metastases
5. 20.06.2022
   Dr. Sonja Woermann, Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, US
   The Role of APOBEC3A in Pancreatic Cancer
6. 05.09.2022
   Prof. Dr. med. Diana Steinmann, Clinic for Radiotherapy and Special Oncology (MHH)
   Complementary Medicine in Oncology - What Else Can Patients Do?
7. 10.10.2022
   Dr. Arnab Nayak, Institute for Molecular and Cell Physiology (MHH)
   Cachexia and the SUMO pathway – a new paradigm of muscle wasting disorders
8. 24.10.2022
   Dr. Benedikt Westphalen, CCC Munich (LMU)
   Access to innovative care - scaling precision oncology
9. 07.11.2022
   Dr. Asha Balakrishnan, Department of Gastroenterology, Hepatology and Endocrinology (MHH)
   Interactions between cellular processes, metabolic pathways, and miRNAs in HCC
10. 05.12.2022
    Dr. Shiv Singh, Department of Gastroenterology, Gastrointestinal Oncology, and Endocrinology (UMG)
    Cell-extrinsic and –intrinsic mechanisms in pancreatic cancer heterogeneity and therapy response
11. 12.12.2022
    Prof. Dr. med. Jens Siveke, WTZ Essen
    Translational approaches in pancreatic cancer

12. 09.01.2023
    Dr. Benedikt Nilges, ESBC Leuven
    Studying tumor heterogeneity and microenvironments with single cell spatial transcriptomics
13. 06.02.2023
    Dr. Sara Haag (TRAIN Niedersachsen) **& PD Dr. Sara Nußbeck** (UMG)
    Lower Saxony Unified Biobank – An Infrastructure to Support Translational Research
14. 20.02.2023
    Alexander Berg & Dr. Liat Hayardeny-Brueck (both UMG Knowledge and Technology Transfer)
    From Bench to Bedside – How the UMG Accelerates Drug Development
15. 01.03.2023
    Prof. Dr. Maximilian Reichert, TU München
    Functionalizing patient-derived organoids to model intra-tumoral heterogeneity in pancreatic cancer
16. 17.04.2023
    Prof. Dr. Marc Schmidt-Supprian, LMU München
    Balancing B-Cell Responses between Protective Immunity, Autoimmunity and Lymphomagenesis
17. 15.05.2023
    Prof. Dr. Ulrich Keller, Charité Berlin
    The activated MYC-SUMO axis in cancer: mechanisms and targeting
18. 26.06.2023
    Prof. Dr. Alexander Kleger, Ulm
    Epithelial genotypes determine niche reprogramming during pancreatic carcinogenesis
19. 04.09.2023
    Dr. Christian Braun, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich
    Targeting imbalanced transcription programs in cancer
20. 08.11.2023
    Alan Coy, Roche Pharma
    Digitalization in Oncology
21. 04.12.2023
    Dr. Siegfried Hauch, Qiagen Gmbh
    Matched Analysis of Liquid Biopsy Components in ER+ Her2-Breast Cancer – Is there a Master Analyte?
22. 18.12.2023
    Prof. Dr. Michael Altenbuchinger, UMG
    High-dimensional statistical approaches for (multi-)omics and spatial transcriptomics data: applications to cancer research
23. 15.01.2024
    Prof. Dr. Svenja Meierjohann, Universität Würzburg
    Stress adaptation in melanoma: the role of NRF2
24. 20.02.2024
    Prof. Dr. Hana Algül, Technische Universität München
    Pancreatic Carcinoma - What's Standard, What's Next?
25. 04.03.2024
    Prof. Dr. Uta-Maria Bauer, Philipps Universität Marburg
    PRMTs - important players in human malignancies

26. 11.03.2024
Prof. Dr. Martin-Leo Hansmann, Goethe Universität Frankfurt
Strategic lymph node diagnostics in 3D and movement-4D
27. 08.04.2024
Prof. Dr. Elias Arnér, Karolinska Institutet Stockholm
Small molecule inhibitors and chemical degraders (PROTACs) of oncogenic targets
28. 29.04.2024
Prof. Dr Christian Reinhardt, West German Cancer Center Essen
Mouse models of aggressive lymphoma as preclinical avatars to dissect biology and for the development of therapeutic strategies
29. 05.08.2024
Prof. Dr. Wolgang Sippl, Martin-Luther-Universität Halle-Wittenberg
Small molecule inhibitors and chemical degraders (PROTACs) of oncogenic targets
30. 02.09.2024
Prof. Dr. Florian Heidel, Medizinische Hochschule Hannover
Effectors of malignant JAK-signaling
31. 11.11.2024
Prof. Dr. Elmar Wolf, Christian-Albrechts-Universität zu Kiel
Targeting the oncogenic function of MYC in PDAC
32. 02.12.2024
Prof. Dr. Martin Sos, Ludwig-Maximilians-Universität München
Exploiting molecular dependencies in lung cancer
33. 15.01.2025
Dr. Dan Lu, Harvard Medical School
Dynamic combinatorial p53 post-translational modifications regulate cell fate
34. 10.02.2025
Prof. Dr. Gunnar Schotta, Ludwig Maximilians Universität München
Silent Invaders: Unraveling the Regulation of Endogenous Retroviruses
35. 10.03.2025
Prof. Dr. Stefan Hüttelmaier, Martin-Luther-Universität Halle-Wittenberg
Targeting RNS Binding Proteins (RBPs) and microRNAs in Cancer Therapy
36. 28.04.2025
Prof. Dr. Joanna Kalucka, Aarhus University
Crosstalk Between Metabolic and Immune Pathways in Regulating Vascular Biology
37. 05.05.2025
Prof. Dr. Daniel Krappmann, LMU München
MALT1 paracaspase - a double-edged sword in cancer therapy
38. 02.06.2025
Prof. Dr. Mathias Heikenwälder, DKFZ Heidelberg
Immune microenvironment in liver cancer - the importance of metabolic alterations in health and in disease: Consequences for therapy
39. 30.06.2025
Prof. Dr. Thomas Brabletz, Universität Erlangen
EMT AND CELL PLASTICITY IN CANCER - DRIVING FORCE AND THERAPEUTIC TARGET
40. 25.08.2025
Prof. Dr. Roland Schwarz, Universität Köln & ICCB
Clonal evolution in chromosomally unstable tumours

41. 15.09.2025
Dr. Markus Schick, Astra Zeneca
From data to decision: AI-based computational pathology to guide ADC use in Oncology
42. 29.09.2025
Prof. Dr. Jacob Piehler, Universität Osnabrück
Structural and functional plasticity of cytokine receptor signaling complexes
43. 06.10.2025
Prof. Dr. Ana Martin-Villalba, DKFZ Heidelberg
The Perils and Promise of Polyploid Cells in the Pancreas. Implications for Tissue Remodeling, Genomic Instability, and Disease Progression
44. 20.10.2025
Prof. Dr. Tilmann Brummer, Universität Freiburg
Towards more effective therapies for BRAF driven cancers – from molecular mechanisms to molecular tumour boards (and back)
45. 17.11.2025
Prof. Dr. Jürgen Ruland, TU München
Immune Receptor Signals in T-cell Lymphoma
46. 24.11.2025
Prof. Dr. Dominik Wolf, Medizinische Universität Innsbruck
Myeloid inflammation - a cancer hallmark
47. 01.12.2025
Dr. Michael Lidschreiber, Max Planck Institute for Interdisciplinary Sciences
Transcription of the genome: molecular mechanisms and cellular regulation
48. 15.12.2025
Dr. Marieke Oudelaar, Max Planck Institute for Interdisciplinary Sciences
Mechanisms that drive 3D genome folding and their function in gene regulation
49. 04.02.2026
Dr. Florian Perner, Medizinische Hochschule Hannover
Menin inhibition in acute myeloid leukemia: resistance and persistence limiting long-term responses
50. 17.03.2026
Prof. Dr. Johannes Betge, Universität Mannheim/DKFZ Heidelberg
Analysis of vulnerabilities and resistance mechanisms of colorectal cancer using patient-derived organoids
51. 13.04.2026
Prof. Dr. Julia Jellusova, TUM und **Prof. Dr. Christian Braun,** Universität Frankfurt
Dealing with Stress: From B Cell Homeostasis to Cancer Vulnerabilities
20.04.2026
52. **Prof. Dr. Oliver Krämer,** Universität Mainz
The HDAC1/HDAC2-SIAH2 signaling node links proteasomal degradation of oncogenic JAK2V617F to reactive oxygen species-dependent apoptosis through STAT1-SMIM20
53. 27.04.2026
Prof. Dr. Florian Greten, Universität Frankfurt
Cell Plasticity in Colorectal Cancer
54. **Prof. Dr. Carsten Marr,** LMU
Diagnosing Blood Diseases with AI
55. **Prof. Dr. Gaurav Ahuja,** IIIT Delhi
Decoding and Designing Bioactive Molecules with Generative AI

56. 29.06.2026
Dr. Daniel Wiseman, Manchester University
Chronic Myelomonocytic Leukaemia: Escaping The Labyrinth?

57. 13.07.2026
Prof. Dr. Michael Hölzel, University of Bonn
AI-Based Protein Design: Recent Advances and Opportunities for Cancer Research

58. 18.08.2026
Robert A. Beckman, Georgetown University
The Generalized Randomized Confirmatory Basket Trial to Improve Drug Development Efficiency

59. **Dr. Peter Bailey,** Botton-Champalimaud Pancreatic Cancer Center, Lissabon
High Definition Profiling of Pancreatic Cancer Dissemination

60. **Prof. Dr. Philippe Gaulard,**
TFH lymphomas: lessons from the past, towards the future